Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...

AIA, J.P. Morgan Asset Management and International Finance Corp are among the companies vying for shares in the Malaysian ...

Whether or not this is the year that some of the biggest AI IPOs hit the public markets, there’s certainly a packed pipeline ...

Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

CNBC’s “Closing Bell Overtime” team discusses the outlook for IPOs after having the biggest IPO week in years with Brett ...

Generate Biomedicines’ IPO aims to fund Phase 3 GB-0895 for severe asthma/COPD and expand its pipeline. Learn more about GENB ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

The board of NSE approved undertaking the IPO through a pure offer for sale (OFS) by existing shareholders. The IPO will ...

SpaceX is better positioned to capitalize on many of the space initiatives than Rocket Lab. Read why SPACE is a Buy and why RKLB stock is a Hold.

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...

Entering the phone business could bolster SpaceX’s revenues as the company begins marketing its IPO, but the smartphone ...

For U.S. initial public offerings, 2026 is starting out as a slow burn, with 24 IPOs filed so far, down 11.1% from the same period in 2025, according to Renaissance Capital.